Financial_NNP Statements_NNP 111_CD 23_CD POST-RETIREMENT_NNP BENEFITS_NNP CONTINUED_VBD Reserves_NNS Included_VBN within_IN the_DT retained_VBN earnings_NNS reserve_NN is_VBZ the_DT actuarial_JJ reserve_NN ._.
Movements_NNS on_IN this_DT reserve_NN are_VBP as_IN follows_VBZ :_: 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN 1_CD January_NNP 303_CD 167_CD Actuarial_JJ losses_NNS 35 179 240_CD Deferred_JJ tax_NN 10_CD 43_CD 73_CD At_IN 31_CD December_NNP 328 303 167_CD 24_CD EMPLOYEE_NN COSTS_NNS AND_CC SHARE_VBP OPTION_NNP PLANS_VBZ FOR_IN EMPLOYEES_NNS Employee_NN costs_VBZ The_DT average_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP is_VBZ set_VBN out_RP in_IN the_DT table_NN below_IN ._.
In_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, this_DT includes_VBZ part-time_JJ employees_NNS :_: Employees_NNS 2005 2004 2003_CD Average_JJ number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP in_IN :_: UK_NNP 11,600_CD 11,500_CD 11,100_CD Continental_NNP Europe_NNP 26,200_CD 25,600_CD 23,900_CD The_DT Americas_NNPS 17,900_CD 18,500_CD 17,900_CD Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP 9,200_CD 8,600_CD 8,100_CD Continuing_VBG operations_NNS 64,900_CD 64,200_CD 61,000_CD The_DT number_NN of_IN people_NNS employed_VBN by_IN the_DT Group_NNP at_IN the_DT end_NN of_IN 2005_CD was_VBD 65,300_CD 2004_CD 64,200_CD ,_, 2003_CD 62,600_CD ._.
The_DT costs_NNS incurred_VBN during_IN the_DT year_NN in_IN respect_NN of_IN these_DT employees_NNS were_VBD :_: 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Salaries_NNS 4,270_CD 4,078_CD 3,587_CD Social_NNP security_NN costs_NNS 670 644 526_CD Pension_NN costs_NNS 265 280 281_CD Other_JJ employment_NN costs_NNS 556 450 489_CD 5,761_CD 5,452_CD 4,883_CD Severance_NN costs_NNS of_IN $_$ 29m_CD are_VBP not_RB included_VBN above_IN 2004_CD $_$ nil_CD ,_, 2003_CD $_$ nil_JJ ._.
The_DT Directors_NNS believe_VBP that_IN ,_, together_RB with_IN the_DT basic_JJ salary_NN system_NN ,_, the_DT Groups_NNS employee_NN incentive_NN schemes_NNS provide_VBP competitive_JJ and_CC market-related_JJ packages_NNS to_TO motivate_VB employees_NNS ._.
They_PRP should_MD also_RB align_VB the_DT interests_NNS of_IN employees_NNS with_IN those_DT of_IN shareholders_NNS ,_, as_IN a_DT whole_JJ ,_, through_IN long_JJ term_NN share_NN ownership_NN in_IN the_DT Company_NN ._.
The_DT Groups_NNS current_JJ UK_NNP ,_, Swedish_NNP and_CC US_NNP schemes_NNS are_VBP described_VBN below_IN :_: other_JJ arrangements_NNS apply_VBP elsewhere_RB ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 112_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 24_CD EMPLOYEE_NN COSTS_NNS AND_CC SHARE_VBP OPTION_NNP PLANS_VBZ FOR_IN EMPLOYEES_NNS CONTINUED_VBD The_DT AstraZeneca_NNP UK_NNP Performance_NNP Bonus_NNP Plan_NNP Employees_NNS of_IN participating_VBG AstraZeneca_NNP UK_NNP companies_NNS are_VBP invited_VBN to_TO participate_VB in_IN this_DT bonus_NN plan_NN ,_, which_WDT rewards_VBZ strong_JJ individual_JJ performance_NN ._.
Bonuses_NNS are_VBP paid_VBN partly_RB in_IN the_DT form_NN of_IN Ordinary_NNP Shares_NNP in_IN the_DT Company_NN under_IN the_DT Inland_NNP Revenue-approved_JJ AstraZeneca_NNP All-Employee_NNP Share_NNP Plan_NNP and_CC up_RB to_TO a_DT maximum_JJ annual_JJ value_NN of_IN 3,000_CD and_CC partly_RB in_IN cash_NN ._.
A_DT tax-efficient_JJ share_NN retention_NN scheme_NN ,_, under_IN which_WDT employees_NNS leave_VBP their_PRP$ bonus_NN shares_NNS in_IN trust_NN for_IN three_CD to_TO five_CD years_NNS ,_, forms_NNS part_NN of_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
The_DT Company_NN also_RB offers_VBZ UK_NNP employees_NNS the_DT opportunity_NN to_TO buy_VB Partnership_NNP Shares_NNP Ordinary_NNP Shares_NNP under_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
Employees_NNS may_MD invest_VB up_RP to_TO 1,500_CD over_IN a_DT 12_CD month_NN accumulation_NN period_NN and_CC purchase_NN Partnership_NNP Shares_NNP in_IN the_DT Company_NN with_IN the_DT total_JJ proceeds_NNS at_IN the_DT end_NN of_IN the_DT period_NN ._.
The_DT purchase_NN price_NN for_IN the_DT shares_NNS is_VBZ the_DT lower_JJR of_IN the_DT price_NN at_IN the_DT beginning_NN or_CC the_DT end_NN of_IN the_DT 12_CD month_NN period_NN ._.
A_DT tax_NN efficient_JJ share_NN retention_NN scheme_NN is_VBZ also_RB available_JJ in_IN respect_NN of_IN Partnership_NNP Shares_NNP ._.
At_IN the_DT Companys_NNPS AGM_NNP in_IN 2002_CD ,_, shareholders_NNS approved_VBD the_DT issue_NN of_IN new_JJ shares_NNS for_IN the_DT purposes_NNS of_IN the_DT All-Employee_NNP Share_NN Plan_NN ._.
The_DT AstraZeneca_NNP Executive_NNP Annual_JJ Bonus_NNP Scheme_NNP This_DT scheme_NN is_VBZ a_DT performance_NN bonus_NN scheme_NN for_IN Directors_NNS and_CC senior_JJ employees_NNS who_WP do_VBP not_RB participate_VB in_IN the_DT AstraZeneca_NNP UK_NNP Performance_NNP Bonus_NNP Plan_NNP ._.
Annual_JJ bonuses_NNS are_VBP paid_VBN in_IN cash_NN and_CC reflect_VB both_DT corporate_JJ and_CC individual_JJ performance_NN measures_NNS ._.
The_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN to_TO reduce_VB or_CC withhold_VB bonuses_NNS if_IN business_NN performance_NN falls_VBZ sufficiently_RB short_JJ of_IN expectations_NNS in_IN any_DT year_NN such_JJ as_IN to_TO make_VB the_DT payment_NN of_IN bonuses_NNS inappropriate_JJ ._.
The_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN UK_NNP employees_NNS may_MD make_VB regular_JJ monthly_JJ savings_NNS contributions_NNS over_IN a_DT three_CD or_CC five_CD year_NN period_NN and_CC may_MD apply_VB for_IN options_NNS to_TO acquire_VB AstraZeneca_NNP Ordinary_NNP Shares_NNP ._.
Further_JJ details_NNS are_VBP set_VBN out_RP below_IN ._.
The_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN This_DT is_VBZ a_DT share_NN option_NN plan_NN for_IN employees_NNS of_IN participating_VBG AstraZeneca_NNP Group_NNP companies_NNS which_WDT was_VBD approved_VBN by_IN shareholders_NNS at_IN the_DT Companys_NNPS AGM_NNP in_IN 2000_CD ._.
The_DT first_JJ grant_NN of_IN options_NNS occurred_VBD in_IN August_NNP 2000_CD ._.
The_DT main_JJ grant_NN of_IN options_NNS in_IN 2005_CD under_IN the_DT plan_NN was_VBD in_IN March_NNP ,_, with_IN a_DT further_JJ smaller_JJR grant_NN in_IN August_NNP ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN and_CC ,_, in_IN accordance_NN with_IN the_DT rules_NNS of_IN the_DT plan_NN ,_, conducted_VBD a_DT review_NN of_IN the_DT plan_NN in_IN 2004_CD ._.
The_DT AstraZeneca_NNP Performance_NNP Share_NNP Plan_NNP This_DT plan_NN was_VBD approved_VBN by_IN shareholders_NNS in_IN 2005_CD for_IN a_DT period_NN of_IN 10_CD years_NNS ._.
Generally_RB ,_, awards_NNS can_MD be_VB granted_VBN at_IN any_DT time_NN ,_, but_CC not_RB during_IN a_DT close_JJ period_NN of_IN the_DT Company_NN ._.
The_DT first_JJ grant_NN of_IN awards_NNS was_VBD made_VBN in_IN June_NNP 2005_CD ._.
Thereafter_RB ,_, the_DT majority_NN of_IN awards_NNS are_VBP likely_JJ to_TO be_VB granted_VBN at_IN or_CC around_IN the_DT same_JJ time_NN as_IN options_NNS are_VBP granted_VBN under_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
Awards_NNS granted_VBN under_IN the_DT plan_NN vest_NN after_IN three_CD years_NNS depending_VBG on_IN the_DT performance_NN of_IN the_DT Company_NN compared_VBN to_TO that_DT of_IN a_DT selected_VBN peer_VBP group_NN of_IN other_JJ pharmaceutical_JJ companies_NNS ._.
The_DT Remuneration_NNP Committee_NNP has_VBZ responsibility_NN for_IN agreeing_VBG any_DT awards_NNS under_IN the_DT plan_NN and_CC for_IN setting_VBG the_DT policy_NN for_IN the_DT way_NN in_IN which_WDT the_DT plan_NN should_MD be_VB operated_VBN ,_, including_VBG agreeing_VBG performance_NN targets_NNS and_CC which_WDT employees_NNS should_MD be_VB invited_VBN to_TO participate_VB ._.
A_DT fuller_JJR description_NN of_IN this_DT plan_NN can_MD be_VB found_VBN on_IN page_NN 73_CD in_IN the_DT Directors_NNS Remuneration_NNP Report_NNP ._.
Sweden_NNP In_IN Sweden_NNP an_DT all-employee_JJ performance_NN bonus_NN plan_NN is_VBZ in_IN operation_NN ,_, which_WDT rewards_VBZ strong_JJ individual_JJ performance_NN ._.
Bonuses_NNS are_VBP paid_VBN partly_RB in_IN the_DT form_NN of_IN Ordinary_NNP Shares_NNP in_IN the_DT Company_NN and_CC partly_RB in_IN cash_NN ._.
Existing_VBG Ordinary_NNP Shares_NNP purchased_VBD in_IN the_DT market_NN are_VBP used_VBN to_TO pay_VB bonuses_NNS awarded_VBN under_IN the_DT plan_NN ._.
The_DT AstraZeneca_NNP Executive_NNP Annual_JJ Bonus_NNP Scheme_NNP and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN both_DT operate_VBP in_IN respect_NN of_IN relevant_JJ AstraZeneca_NNP employees_NNS in_IN Sweden_NNP ._.
US_NNP In_IN the_DT US_NNP ,_, there_EX are_VBP two_CD all-employee_JJ performance_NN bonus_NN plans_NNS in_IN operation_NN ,_, which_WDT reward_VBP strong_JJ individual_JJ performance_NN ._.
There_EX are_VBP also_RB two_CD senior_JJ staff_NN incentive_NN schemes_NNS ,_, under_IN which_WDT approximately_RB 140_CD participants_NNS are_VBP awarded_VBN either_DT AstraZeneca_NNP ADSs_NNPS or_CC stock_NN appreciation_NN rights_NNS related_VBN to_TO AstraZeneca_NNP ADSs_NNP ._.
AstraZeneca_NNP ADSs_NNP necessary_JJ to_TO satisfy_VB the_DT awards_NNS are_VBP purchased_VBN in_IN the_DT market_NN ._.
The_DT AstraZeneca_NNP Share_NN Option_NN Plan_NNP operates_VBZ in_IN respect_NN of_IN relevant_JJ AstraZeneca_NNP employees_NNS in_IN the_DT US_NNP ._.
Share_NN option_NN plans_VBZ At_IN 31_CD December_NNP 2005_CD ,_, there_EX were_VBD options_NNS outstanding_JJ under_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, the_DT Astra_NNP Shareholder_NN Value_NNP Incentive_NNP Plan_NNP ,_, the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN ,_, the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN and_CC the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
1_CD Summary_NNP of_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NNP Eligibility_NNP Any_DT AstraZeneca_NNP employee_NN may_MD be_VB recommended_VBN from_IN time_NN to_TO time_NN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN including_VBG as_IN regards_VBZ which_WDT employees_NNS will_MD be_VB eligible_JJ to_TO participate_VB ._.
Grant_NNP of_IN options_NNS Options_NNS may_MD be_VB granted_VBN at_IN any_DT time_NN other_JJ than_IN during_IN a_DT close_JJ period_NN ._.
The_DT grant_NN of_IN options_NNS is_VBZ supervised_VBN by_IN the_DT Remuneration_NNP Committee_NNP ,_, which_WDT is_VBZ comprised_VBN wholly_RB of_IN Non-Executive_JJ Directors_NNS ._.
No_DT payment_NN is_VBZ required_VBN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
Options_NNS may_MD be_VB granted_VBN over_IN AstraZeneca_NNP Ordinary_NNP Shares_NNP or_CC ADSs_NNP ._.
Financial_NNP Statements_NNP 113_CD 24_CD EMPLOYEE_NN COSTS_NNS AND_CC SHARE_VBP OPTION_NNP PLANS_VBZ FOR_IN EMPLOYEES_NNS CONTINUED_VBD Acquisition_NNP price_NN The_DT price_NN per_IN Ordinary_NNP Share_NNP payable_JJ upon_IN the_DT exercise_NN of_IN an_DT option_NN will_MD not_RB be_VB less_JJR than_IN an_DT amount_NN equal_JJ to_TO the_DT average_NN of_IN the_DT middle-market_JJ closing_NN price_NN for_IN an_DT Ordinary_NNP Share_NN or_CC ADS_NNPS of_IN the_DT Company_NN on_IN the_DT London_NNP or_CC New_NNP York_NNP Stock_NNP Exchange_NNP on_IN the_DT three_CD consecutive_JJ dealing_VBG days_NNS immediately_RB before_IN the_DT date_NN of_IN grant_NN or_CC as_IN otherwise_RB agreed_VBN with_IN HM_NNP Revenue_NNP &_CC Customs_NNP ._.
Where_WRB the_DT option_NN is_VBZ an_DT option_NN to_TO subscribe_VB ,_, the_DT price_NN payable_JJ upon_IN exercise_NN can_MD not_RB be_VB less_JJR than_IN the_DT nominal_JJ value_NN of_IN an_DT Ordinary_NNP Share_NN of_IN the_DT Company_NN ._.
Exercise_NN of_IN options_NNS An_DT option_NN will_MD normally_RB be_VB exercisable_JJ between_IN three_CD and_CC 10_CD years_NNS following_VBG its_PRP$ grant_NN provided_VBD any_DT relevant_JJ performance_NN condition_NN has_VBZ been_VBN satisfied_VBN ._.
Options_NNS may_MD be_VB satisfied_VBN by_IN the_DT issue_NN of_IN new_JJ Ordinary_NNP Shares_NNP or_CC by_IN existing_VBG Ordinary_NNP Shares_NNP purchased_VBD in_IN the_DT market_NN ._.
The_DT Remuneration_NNP Committee_NNP sets_VBZ the_DT policy_NN for_IN the_DT Companys_NNP operation_NN of_IN the_DT plan_NN including_VBG as_IN regards_VBZ whether_IN any_DT performance_NN target_NN s_PRP will_MD apply_VB to_TO the_DT grant_NN and_CC or_CC exercise_NN of_IN each_DT eligible_JJ employees_NNS option_NN ._.
Options_NNS normally_RB lapse_NN on_IN cessation_NN of_IN employment_NN ._.
Exercise_NN is_VBZ ,_, however_RB ,_, permitted_VBD for_IN a_DT limited_JJ period_NN following_VBG cessation_NN of_IN employment_NN either_CC for_IN reasons_NNS of_IN injury_NN or_CC disability_NN ,_, redundancy_NN or_CC retirement_NN ,_, or_CC at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP ,_, and_CC on_IN an_DT amalgamation_NN ,_, take-over_NN or_CC winding-up_NN of_IN the_DT Company_NN ._.
2_CD Summary_NNP of_IN the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN The_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN was_VBD approved_VBN by_IN shareholders_NNS in_IN 1994_CD for_IN a_DT period_NN of_IN 10_CD years_NNS ._.
The_DT last_JJ grant_NN of_IN options_NNS under_IN this_DT scheme_NN was_VBD made_VBN in_IN September_NNP 2002_CD ._.
In_IN 2003_CD ,_, shareholders_NNS approved_VBD the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN for_IN a_DT period_NN of_IN 10_CD years_NNS ._.
The_DT first_JJ grant_NN of_IN options_NNS under_IN this_DT plan_NN was_VBD made_VBN in_IN September_NNP 2003_CD ._.
The_DT following_JJ sections_NNS apply_VBP to_TO both_DT the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT AstraZeneca_NNP Savings-Related_NNP Share_NNP Option_NN Plan_NN ,_, which_WDT have_VBP broadly_RB similar_JJ rules_NNS ._.
Eligibility_NNP UK-resident_NNP employees_NNS of_IN participating_VBG AstraZeneca_NNP companies_NNS are_VBP automatically_RB eligible_JJ to_TO participate_VB ._.
Grant_NNP of_IN options_NNS Invitations_NNS to_TO apply_VB for_IN options_NNS may_MD be_VB issued_VBN within_IN six_CD weeks_NNS after_IN the_DT announcement_NN by_IN the_DT Company_NN of_IN its_PRP$ results_NNS for_IN any_DT period_NN and_CC at_IN other_JJ times_NNS in_IN circumstances_NNS considered_VBN to_TO be_VB exceptional_JJ by_IN the_DT Directors_NNS ._.
No_DT invitations_NNS may_MD be_VB issued_VBN later_RB than_IN 10_CD years_NNS after_IN the_DT approval_NN of_IN the_DT scheme_NN by_IN shareholders_NNS ._.
Options_NNS may_MD only_RB be_VB granted_VBN to_TO employees_NNS who_WP enter_VBP into_IN HM_NNP Revenue_NNP &_CC Customs-approved_JJ savings_NNS contracts_NNS with_IN the_DT savings_NNS body_NN nominated_VBN by_IN the_DT Company_NN ,_, under_IN which_WDT monthly_JJ savings_NNS of_IN a_DT fixed_VBN amount_NN currently_RB not_RB less_JJR than_IN 5_CD nor_CC more_JJR than_IN 250_CD are_VBP made_VBN over_RP a_DT period_NN of_IN three_CD or_CC five_CD years_NNS ._.
The_DT number_NN of_IN Ordinary_NNP Shares_NNP over_IN which_WDT an_DT option_NN is_VBZ granted_VBN will_MD be_VB such_JJ that_IN the_DT total_JJ amount_NN payable_JJ on_IN its_PRP$ exercise_NN will_MD be_VB the_DT proceeds_NNS on_IN maturity_NN of_IN the_DT related_JJ savings_NNS contract_NN ._.
No_DT payment_NN will_MD be_VB required_VBN for_IN the_DT grant_NN of_IN an_DT option_NN ._.
Individual_JJ participation_NN Monthly_JJ savings_NNS by_IN an_DT employee_NN under_IN all_DT savings_NNS contracts_NNS linked_VBN to_TO options_NNS granted_VBN under_IN any_DT Save_NNP As_IN You_PRP Earn_VBP scheme_NN may_MD not_RB exceed_VB 250_CD or_CC such_JJ lower_JJR amounts_NNS as_IN may_MD be_VB determined_VBN by_IN the_DT Directors_NNS ._.
Acquisition_NNP price_NN The_DT price_NN per_IN Ordinary_NNP Share_NNP payable_JJ upon_IN the_DT exercise_NN of_IN an_DT option_NN will_MD not_RB normally_RB be_VB less_JJR than_IN the_DT higher_JJR of_IN :_: a_DT 90_CD %_NN of_IN the_DT arithmetical_JJ average_NN of_IN the_DT middle-market_JJ quotations_NNS for_IN an_DT Ordinary_NNP Share_NN on_IN the_DT London_NNP Stock_NNP Exchange_NNP on_IN three_CD consecutive_JJ dealing_VBG days_NNS shortly_RB before_IN the_DT date_NN on_IN which_WDT invitations_NNS to_TO apply_VB for_IN options_NNS are_VBP issued_VBN provided_VBN that_IN no_DT such_JJ day_NN may_MD fall_VB before_IN the_DT Company_NN last_JJ announced_VBD its_PRP$ results_NNS for_IN any_DT period_NN or_CC such_JJ other_JJ dealing_VBG day_NN or_CC days_NNS falling_VBG within_IN the_DT six_CD week_NN period_NN for_IN the_DT issue_NN of_IN invitations_NNS ,_, as_IN the_DT Directors_NNS may_MD decide_VB :_: and_CC b_NN the_DT nominal_JJ value_NN of_IN an_DT Ordinary_NNP Share_NN unless_IN the_DT option_NN is_VBZ expressed_VBN to_TO relate_VB only_RB to_TO existing_VBG Ordinary_NNP Shares_NNP ._.
Exercise_NN of_IN options_NNS An_DT option_NN will_MD normally_RB be_VB exercisable_JJ only_RB for_IN six_CD months_NNS commencing_VBG on_IN the_DT third_JJ or_CC fifth_JJ anniversary_NN of_IN the_DT commencement_NN of_IN the_DT related_JJ savings_NNS contract_NN ._.
Options_NNS are_VBP satisfied_VBN by_IN the_DT issue_NN of_IN new_JJ Ordinary_NNP Shares_NNP ._.
Exercise_NN is_VBZ ,_, however_RB ,_, permitted_VBD for_IN a_DT limited_JJ period_NN irrespective_RB of_IN the_DT period_NN during_IN which_WDT the_DT option_NN has_VBZ been_VBN held_VBN following_VBG cessation_NN of_IN employment_NN in_IN certain_JJ compassionate_JJ circumstances_NNS or_CC where_WRB an_DT option_NN has_VBZ been_VBN held_VBN for_IN more_JJR than_IN three_CD years_NNS except_IN on_IN dismissal_NN for_IN misconduct_NN and_CC on_IN an_DT amalgamation_NN ,_, take-over_NN or_CC winding-up_NN of_IN the_DT Company_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC 114_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 24_CD EMPLOYEE_NN COSTS_NNS AND_CC SHARE_VBP OPTION_NNP PLANS_VBZ FOR_IN EMPLOYEES_NNS CONTINUED_VBD 3_CD Summary_NNP of_IN the_DT Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NNP The_NNP Zeneca_NNP 1994_CD Executive_NNP Share_NNP Option_NN Scheme_NN was_VBD introduced_VBN in_IN 1994_CD ._.
The_DT last_JJ date_NN for_IN the_DT grant_NN of_IN options_NNS was_VBD 16_CD March_NNP 2000_CD and_CC the_DT scheme_NN has_VBZ been_VBN replaced_VBN by_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
Options_NNS granted_VBN under_IN the_DT 1994_CD scheme_NN are_VBP normally_RB exercisable_JJ between_IN three_CD and_CC 10_CD years_NNS following_VBG grant_NN ,_, provided_VBD the_DT relevant_JJ performance_NN condition_NN has_VBZ been_VBN satisfied_VBN ._.
The_DT performance_NN condition_NN applicable_JJ to_TO the_DT 1994_CD scheme_NN was_VBD that_IN earnings_NNS per_IN share_NN must_MD have_VB grown_VBN by_IN at_IN least_JJS the_DT increase_NN in_IN the_DT UK_NNP Retail_NNP Price_NNP Index_NNP over_IN three_CD years_NNS plus_CC 3_CD %_NN per_IN annum_NN ._.
Satisfaction_NN of_IN this_DT condition_NN was_VBD tested_VBN annually_RB by_IN reference_NN to_TO the_DT audited_JJ financial_JJ statements_NNS ._.
All_DT options_NNS granted_VBN under_IN the_DT 1994_CD scheme_NN have_VBP become_VBN exercisable_JJ ,_, the_DT performance_NN conditions_NNS having_VBG been_VBN satisfied_VBN ._.
4_CD Summary_NNP of_IN the_DT Astra_NNP Shareholder_NN Value_NNP Incentive_NNP Plan_NNP In_IN 1996_CD ,_, Astra_NNP established_VBD a_DT stock_NN option_NN plan_NN for_IN some_DT 100_CD Astra_NNP employees_NNS in_IN key_JJ senior_JJ positions_NNS ._.
The_DT plan_NN is_VBZ no_RB longer_RB used_VBN for_IN the_DT grant_NN of_IN options_NNS and_CC has_VBZ been_VBN superseded_VBN by_IN the_DT AstraZeneca_NNP Share_NN Option_NN Plan_NN ._.
On_IN completion_NN of_IN Astras_NNP merger_NN with_IN Zeneca_NNP ,_, options_NNS in_IN Astra_NNP shares_NNS granted_VBN under_IN the_DT plan_NN were_VBD replaced_VBN by_IN options_NNS to_TO acquire_VB a_DT number_NN of_IN AstraZeneca_NNP Ordinary_NNP Shares_NNP based_VBN on_IN the_DT exchange_NN ratio_NN used_VBN in_IN the_DT exchange_NN offers_VBZ used_VBN to_TO effect_VB the_DT AstraZeneca_NNP merger_NN ._.
The_DT ratio_NN of_IN AstraZeneca_NNP options_NNS granted_VBN in_IN respect_NN of_IN former_JJ Astra_NNP options_NNS was_VBD 0.5045_CD AstraZeneca_NNP options_NNS for_IN each_DT Astra_NNP option_NN held_VBD ._.
AstraZeneca_NNP Share_NNP Option_NN Plan_NN 1994_CD Scheme_NNP SAYE_NNP Schemes_NNPS ASVIP_NNP Shares_NNP Options_NNPS WAEP_NNP Options_NNPS WAEP_NNP Options_NNPS WAEP_NNP under_IN option_NN WAEP_NNP 000_CD pence_NN 000_CD pence_NN 000_CD pence_NN 000_CD SEK_NNP At_IN 1_CD January_NNP 2003_CD Options_NNPS outstanding_JJ 21,398_CD 3347_CD 9,289_CD 2647_CD 4,065_CD 1987 759 391_CD Movements_NNS during_IN 2003_CD Options_NNS granted_VBN 15,505_CD 2232 551 2211_CD Options_NNS exercised_VBN 52 2468 358 2423_CD 382 2137 151 311_CD Options_NNS forfeited_VBD 1,163_CD 3001 571 2695 282_CD 2192_CD 1_CD 318_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 583_CD 658_CD At_IN 31_CD December_NNP 2003_CD Options_NNPS outstanding_JJ 35,688_CD 2874_CD 8,360_CD 2654_CD 3,952_CD 1988 607 411_CD Movements_NNS during_IN 2004_CD Options_NNS granted_VBN 10,741_CD 2529 550 2262_CD Options_NNS exercised_VBN 329 2787 586 2704_CD 113 2184 114 321_CD Options_NNS forfeited_VBD 1,964_CD 2886 285 2660 276_CD 2199_CD 10_CD 474_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 650_CD 632_CD At_IN 31_CD December_NNP 2004_CD Options_NNPS outstanding_JJ 44,136_CD 2790_CD 7,489_CD 2650_CD 4,113_CD 2005 483 431_CD Movements_NNS during_IN 2005_CD Options_NNS granted_VBN 9,621_CD 2133 606 2257_CD Options_NNS exercised_VBN 1,053_CD 2486_CD 1,259_CD 2601 689 1782_CD 6_CD 442_CD Options_NNS forfeited_VBD 2,625_CD 2800 272 2688 592_CD 2248 168 411_CD Options_NNS lapsed_VBD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN during_IN the_DT year_NN 619_CD 700_CD At_IN 31_CD December_NNP 2005_CD Options_NNPS outstanding_JJ 50,079_CD 2670_CD 5,958_CD 2658_CD 3,438_CD 2053 309 442_CD Range_NNP of_IN exercise_NN prices_NNS 1913p_VBP to_TO 1337p_VB to_TO 1756p_VB to_TO 442_CD SEK_NNP to_TO 3487p_VB 2749p_JJ 2971p_JJ 442_CD SEK_NNP Weighted_VBN average_JJ remaining_VBG contractual_JJ life_NN 2,655_CD days_NNS 1,453_CD days_NNS 1,047_CD days_NNS 23_CD days_NNS Options_NNPS exercisable_JJ 18,969_CD 3291_CD 5,958_CD 2658 191 2456 309_CD 442_CD Weighted_JJ average_JJ exercise_NN price_NN Share_NN options_NNS were_VBD exercised_VBN on_IN a_DT regular_JJ basis_NN throughout_IN the_DT period_NN ._.
Financial_NNP Statements_NNP 115_CD 24_CD EMPLOYEE_NN COSTS_NNS AND_CC SHARE_VBP OPTION_NNP PLANS_VBZ FOR_IN EMPLOYEES_NNS CONTINUED_VBD The_DT fair_JJ value_NN of_IN the_DT options_NNS is_VBZ estimated_VBN at_IN the_DT date_NN of_IN grant_NN using_VBG the_DT Black-Scholes_NNP option_NN pricing_NN model_NN ._.
The_DT following_VBG table_NN gives_VBZ the_DT assumptions_NNS applied_VBD to_TO the_DT options_NNS granted_VBN in_IN the_DT respective_JJ periods_NNS shown_VBN ._.
Expectations_NNS of_IN early_JJ exercise_NN are_VBP incorporated_VBN into_IN the_DT model_NN ._.
2005 2004 2003_CD Average_JJ share_NN price_NN pence_NN 2384 2439 2442_CD Weighted_VBN average_JJ exercise_NN price_NN pence_NN AstraZeneca_NNP Share_NNP Option_NN Plan_NN 2133 2529 2232_CD SAYE_NNP schemes_NNS 2257 2262 2211_CD Weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT period_NN pence_NN AstraZeneca_NNP Share_NNP Option_NN Plan_NN 619 650 583_CD SAYE_NNP schemes_NNS 700 632 658_CD Expected_VBN volatility_NN %_NN 30.0_CD 25.0_CD 25.0_CD Dividend_NN yield_NN %_NN 2.3_CD 2.3_CD 2.0_CD Risk-free_JJ interest_NN rate_NN %_NN 4.3_CD 3.5_CD 4.3_CD Expected_VBN lives_NNS :_: AstraZeneca_NNP Share_NNP Option_NN Plan_NN years_NNS 6.0_CD 6.0_CD 6.0_CD Expected_VBN lives_NNS :_: SAYE_VB schemes_NNS years_NNS 3.9_CD 3.8_CD 4.3_CD The_DT expected_VBN volatility_NN is_VBZ based_VBN on_IN the_DT historic_JJ volatility_NN calculated_VBN based_VBN on_IN the_DT weighted_JJ average_NN remaining_VBG life_NN of_IN the_DT share_NN options_NNS adjusted_VBN for_IN any_DT expected_VBN changes_NNS to_TO future_JJ volatility_NN due_JJ to_TO publicly_RB available_JJ information_NN ._.
No_DT other_JJ features_NNS of_IN options_NNS granted_VBN were_VBD incorporated_VBN into_IN the_DT measurement_NN of_IN fair_JJ value_NN ._.
The_DT charge_NN for_IN share-based_JJ payments_NNS in_IN respect_NN of_IN share_NN options_NNS is_VBZ $_$ 128m_CD 2004_CD $_$ 147m_CD ,_, 2003_CD $_$ 154m_CD which_WDT is_VBZ comprised_VBN entirely_RB of_IN equitysettled_JJ transactions_NNS ._.
AstraZeneca_NNP Performance_NNP Share_NNP Plan_NNP Shares_NNP WAFV_NNP 000_CD pence_NN Shares_NNS awarded_VBN in_IN June_NNP 2005 312 1121_CD The_DT fair_JJ value_NN was_VBD determined_VBN using_VBG a_DT modified_VBN version_NN of_IN the_DT binomial_JJ model_NN ._.
This_DT method_NN incorporated_VBN expected_VBN dividends_NNS but_CC no_DT other_JJ features_NNS into_IN the_DT measurements_NNS of_IN fair_JJ value_NN ._.
US_NNP incentive_NN share_NN schemes_NNS Shares_NNP WAFV_NNP 000_CD $_$ 1,032_CD 41.77_CD Weighted_VBN average_JJ fair_JJ value_NN The_DT charge_NN for_IN share-based_JJ payments_NNS in_IN respect_NN of_IN the_DT AstraZeneca_NNP Performance_NNP Share_NNP Plan_NNP and_CC the_DT US_NNP incentive_NN share_NN schemes_NNS is_VBZ $_$ 15m_CD 2004_CD $_$ 16m_CD ,_, 2003_CD $_$ 9m_CD ._.
